Biotherapeutics comprise a large portion of the treatment options for a wide range of conditions and account for almost half of drugs approvals in 2022. However, the pace of new biologic development has not grown in recent years in part because of the increasing complexity of drug targets and desired performance of these drugs. To keep up with the demand for more effective therapeutics, biopharmaceutical companies need to incorporate enhanced methods and technologies to generate antibodies to accelerate their drug development timeline, from the actual therapeutics to key reagents used throughout the drug development lifecycle.
Scientists at Genovac, a top contract research and manufacturing organization and Bruker Cellular Analysis partner, are combining their expertise in genetic immunization and rapid new technology adoption with the cutting-edge platforms from Bruker Cellular Analysis and Gator Bio to accelerate their antibody discovery campaigns and deliver antibodies of the highest quality for their clients’ needs. In a webinar entitled “Enhance and Expand Anti-ID Antibody Diversity and Affinity Through Genetic Immunization”, speakers from Genovac and Gator Bio will illustrate that these techniques and technologies efficiently identify a robust panel of high-affinity anti-IDs that are ideal for pharmacokinetic applications.
- Genetic immunization unlocks a vast pool of highly diverse, high-affinity antibodies beyond conventional protein immunization
- Combining cutting-edge immunization strategies, multiple hybridoma and single B cell screening platforms, and Gator Bio’s biolayer interferometry enables Genovac to generate and characterize best-in-class anti-IDs
Date & Time: September 14, 2023 9:00 AM PT / 12:00 PM ET / 6:00 PM CET